AMD may be the most common reason behind irreversible vision loss in the developed world.

‘Today's announcement represents a significant milestone for not merely Acucela, but also for the emixustat hydrochloride program and for sufferers worldwide potentially. Emixustat hydrochloride, the initial internally developed compound for Acucela, has a unique system of action in visible cycle modulation, offers oral dosing and the capability to target the visual cycle specifically, representing a novel therapeutic approach for the treating retinal diseases potentially, such as GA connected with dried out AMD.’ Pravin U.’..Neither of these ongoing parties endorse or suggest any commercial products, services, or equipment.

Actavis receives FDA acceptance for Opana ER tablets Actavis, Inc. today announced that it provides received authorization from the U.S. Food and Drug Administration on its Abbreviated New Drug Software for Oxymorphone Hydrochloride Extended-launch Tablets, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg. Related StoriesNovo Nordisk announces FDA approval of Tresiba for diabetes treatmentAllergan settles patent litigation with Amneal related to NAMENDA XR expanded launch capsulesMylan announces U.S.